Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines

Morbidity and Mortality Weekly Report

Volumn 67, Issue 3, 2018, Pages 103-108

  Dooling, Kathleen L ^a   Guo, Angela ^a   Patel, Manisha ^a   Lee, Grace M ^b   Moore, Kelly ^c   Belongia, Edward A ^d   Harpaz, Rafael ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TENNESSEE DEPARTMENT OF HEALTH   (United States)

^d MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; RECOMBINANT VACCINE; VARICELLA ZOSTER VACCINE;

ADVISORY COMMITTEE; AGED; FOOD AND DRUG ADMINISTRATION; HERPES ZOSTER; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; MIDDLE AGED; PRACTICE GUIDELINE; UNITED STATES;

ADVISORY COMMITTEES; AGED; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPETENCE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 85040961865     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6703a5     Document Type: Article

References (33)

1. Food and Drug Administration. Shingrix [package insert]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581605.pdf
2. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748–53. https://doi.org/10.1111/j.1525-1497.2005.0150.x
3. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341–9. https://doi.org/10.4065/82.11.1341
4. Oxman MN, Levin MJ, Johnson GR, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84. https://doi.org/10.1056/NEJMoa051016
5. Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009;63:1386–91 https://doi.org/10.1111/j.1742-1241.2009.02089.x.
6. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(No. RR-5).
7. CDC. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;60:1528.
8. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 2014;63:729–31.
9. CDC. Obtaining and evaluating evidence with grading of recommendations, assessment, development and evaluation (GRADE) for herpes zoster vaccines. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/vaccines/acip/recs/grade/
10. Schmader KE, Oxman MN, Levin MJ, et al.; Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320–8. https://doi.org/10.1093/cid/cis638
11. Morrison VA, Johnson GR, Schmader KE, et al.; Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60:900–9. https://doi.org/10.1093/cid/ciu918
12. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012;54:922–8. https://doi.org/10.1093/cid/cir970
13. Prosser LA. Economic evaluation of vaccination for prevention of herpes zoster and related complications [slides]. Presentation to the Advisory Committee on Immunization Practices; October 25, 2017; Atlanta, Georgia. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-10/zoster-03-prosser.pdf
14. Lal H, Cunningham AL, Godeaux O, et al.; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087–96. https://doi.org/10.1056/NEJMoa1501184
15. Cunningham AL, Lal H, Kovac M, et al.; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019–32. https://doi.org/10.1056/NEJMoa1603800
16. Chesson HW, Laprise JF, Brisson M, Markowitz LE. Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J Infect Dis 2016;213:1694–700. https://doi.org/10.1093/infdis/jiw046
17. Hoerger TJ, Schillie S, Wittenborn JS, et al. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care 2013;36:63–9. https://doi.org/10.2337/dc12-0759
18. Le P, Rothberg MB. Cost-effectiveness of the Adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med 2018;7431. https://doi.org/10.1001/jamainternmed.2017.7431
19. Leidner AJ. Overview of two economic models that assess the cost-effectiveness of herpes zoster vaccinations [slides]. Presentation to the Advisory Committee on Immunization Practices; June 21, 2017; Atlanta, Georgia. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/zoster-04-leidner.pdf
20. Pauksens K, Volpe S, Schwarz TF, et al. Persistence of immune response to an adjuvanted varicella‐zoster virus subunit candidate vaccine for up to year 9 in older adults. Open Forum Infect Dis 2017;4:S415 https://doi.org/10.1093/ofid/ofx163.1039
21. Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in older adults previously vaccinated with a live-attenuated herpes zoster vaccine: a phase III, group-matched, clinical trial. Open Forum Infect Dis 2017;4:S414. https://doi.org/10.1093/ofid/ofx163.1038
22. Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation (GRADE): recombinant zoster vaccine (RZV) and herpes zoster live-attenuated vaccine (ZVL). Atlanta, GA: US Department of Health and Human Services, CDC, Advisory Committee on Immunization Practices; 2017. https://www.cdc.gov/vaccines/acip/recs/grade/herpes-zoster.html
23. Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clin Infect Dis 2017;64:785–93. https://doi.org/10.1093/cid/ciw854
24. Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol 2017;187:161–9.
25. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016a;213:1872–5. https://doi.org/10.1093/infdis/jiw047
26. Baxter R, Bartlett J, Fireman B, et al. Effectiveness of live zoster vaccine in preventing postherpetic neuralgia (PHN). Open Forum Infect Dis 2016;3:128. https://doi.org/10.1093/ofid/ofw194.41
27. Food and Drug Administration. Zostavax [package insert]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2006. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM132831.pdf
28. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep 2016;2016:bcr2015212688. https://doi.org/10.1136/bcr-2015-212688
29. Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine 2017;35:7231–9. https://doi.org/10.1016/j.vaccine.2017.11.013
30. Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine 2018;36:148–54. https://doi.org/10.1016/j.vaccine.2017.11.019
31. Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
32. Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older. J Infect Dis 2017;216:1352–61. https://doi.org/10.1093/infdis/jix481
33. Colindres R. Safety summary of investigational vaccine: Shingrix. [slides]. Presentation to the Advisory Committee on Immunization Practices; February 22, 2017; Atlanta, Georgia. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-02/zoster-02-gsk.pdf